Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Xerosis
(2002): Bariol C+, J Gastroenterol Hepatol 17(2), 135
(2000): Bahl S+, Skin and Aging May, 41
(2000): Oliver SJ+, Clin Immunol 97(2), 109
(1989): Gutierrez-Rodriguez O+, J Rheumatol 16, 158
Mucosal
Xerostomia
(2002): Bariol C+, J Gastroenterol Hepatol 17(2), 135
(2000): Bahl S+, Skin and Aging May, 41
(1999): Monastirli A+, Skin Pharmacol Appl Skin Physiol
12(6), 305
(1996): Huizinga TW+, Ann Rheum Dis 55(11), 833
(1996): Tseng S+, JAmAcadDermatol35, 969 (passim)
(1994): Gardener-Merwin JM+, Ann Rheum Dis 53, 828
(1989): Grinspan D+, JAmAcadDermatol20, 1060
(1989): Gutierrez-Rodriguez O+, J Rheumatol 16, 158
Hair
Hair – alopecia
(1989): Gutierrez-Rodriguez O+, J Rheumatol 16, 158
Nails
Nails – brittle
(1996): Tseng S+, JAmAcadDermatol35, 969 (passim)
Eyes
Corneal abnormalities
(2005): Srinivasan S+, Cornea 24(1), 103
Other
Abdominal pain
(2005): Cuadrado MJ+, Am J Med 118(3), 246
Chills
(2006): Olencki T+, Invest New Drugs 24(4), 321 (with
interleukin-2)
Death
(2001): Diggle GE, Int J Clin 55(9), 627
Fever
(2006): Olencki T+, Invest New Drugs 24(4), 321 (with
interleukin-2)
Gynecomastia
(2002): Pulik M+, Am J Hematol 70(3), 265
Hepatotoxicity
(2006): Hanje AJ+, Pharmacotherapy 26(7), 1018
Hypersensitivity
(2005): Moschella SL, Skinmed 4(1), 19
(2002): Kane S+, J Clin Gastroenterol 35(2), 149
Infections
(2007): Martino M+, Eur J Haematol 78(1), 35 (2 cases)
(2003): Hwu W-J, J Drugs Dermatol 2, 53 (with temozolomide)
Neurotoxicity
(2006): Chan JK+, Gynecol Oncol 103(3), 919 (71%)
(2006): Durk HA, Onkologie 29(12), 582
(2005): Cuadrado MJ+, Am J Med 118(3), 246 (27%)
(2005): Fleming FJ+, Neuromuscul Disord 15(2), 172 (4 cases)
(2005): Moschella SL, Skinmed 4(1), 19
(2005): Tosi P+, Eur J Haematol 74(3), 212 (75%)
(2004): Briani C+, Neurology 62(12), 2288
(2004): Offidani M+, Eur J Haematol 72(6), 403 (39%)
(2004): Strupp C+, Eur J Haematol 72(1), 52 (2 cases)
(2004): Wang TE+, World J Gastroenterol 10(5), 649
(2003): Foldyna D+, Vnitr Lek 49(11), 859 (41%)
(2003): Matthews SJ+, Clin Ther 25(2), 342
(2003): Okafor MC, Pharmacotherapy 23(4), 481
(2002): Grover JK+, Ann Oncol 13(10), 1636
(1992): Awofeso N, Trop Doct 22(3), 139
Thrombosis
(2007): Prince HM+, Leuk Lymphoma 48(1), 46 (3%)
(2006): Anscher MS+, Int J Radiat Oncol Biol Phys 66(2), 477
(2006): Bennett CL+, JAMA 296(21), 2558
(2006): Bringhen S+, Expert Opin Investig Drugs 15(12), 1565
(2006): Doss DS, Clin J Oncol Nurs 10(4), 514 (with
dexamethasone)
(2006): Durk HA, Onkologie 29(12), 582
(2006): Harousseau JL, Future Oncol 2(5), 577 (with
dexamethasone)
(2006): Ikhlaque N+, Am J Hematol 81(6), 420
(2006): Miller KC+, Leuk Lymphoma 47(11), 2339
(2006): Olencki T+, Invest New Drugs 24(4), 321 (with
interleukin-2)
THEOPHYLLINE
(See AMINOPHYLLINE)
Clinically important, potentially hazardous interactions
with: BCG vaccine, cimetidine, erythromycin, nilutamide
THIABENDAZOLE
Synonym: tiabendazole
Trade name: Triasox
Indications: Various infections caused by susceptible helminths
Category: Antibiotic, imidazole; Antihelmintic
Half-life: 1.2 hours
Reactions
THIABENDAZOLE 533
Skin
Angioedema
Dermatitis
(1994): Mancuso G, Contact Dermatitis 31, 207
(1993): Izu R+, Contact Dermatitis 28, 243 (photoaggravated)
Erythema multiforme (5%)
(1982): Sanchez del Rio J+, Actas Dermosifiliogr (Spanish) 73, 125
Fixed eruption (